{"organizations": [], "uuid": "dbf808978d88e257372b5c8d0a99ffda7ed04e9e", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-histogenics-corp-qtrly-net-loss-pe/brief-histogenics-corp-qtrly-net-loss-per-common-share-0-26-idUSASC09SD7", "country": "US", "domain_rank": 408, "title": "BRIEF-Histogenics Corp Qtrly Net Loss Per Common Share $0.26", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-15T12:33:00.000+02:00", "replies_count": 0, "uuid": "dbf808978d88e257372b5c8d0a99ffda7ed04e9e"}, "author": "", "url": "https://www.reuters.com/article/brief-histogenics-corp-qtrly-net-loss-pe/brief-histogenics-corp-qtrly-net-loss-per-common-share-0-26-idUSASC09SD7", "ord_in_thread": 0, "title": "BRIEF-Histogenics Corp Qtrly Net Loss Per Common Share $0.26", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "brief-histogenics corp", "sentiment": "negative"}, {"name": "histogenics corp", "sentiment": "none"}, {"name": "thomson reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 35 AM / Updated 11 minutes ago BRIEF-Histogenics Corp Qtrly Net Loss Per Common Share $0.26 Reuters Staff 1 Min Read March 15 (Reuters) - Histogenics Corp: * ORATION ANNOUNCES FINANCIAL AND OPERATING RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2017 * ‍ NEOCART TOP-LINE PHASE 3 CLINICAL TRIAL DATA AND POTENTIAL BIOLOGICS LICENSE APPLICATION FILING REMAIN ON TRACK FOR Q3 OF 2018​ * ‍AT DECE 31, 2017, CO HAD CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $8.0 MILLION, COMPARED TO $31.9 MILLION AT DECEMBER 31, 2016​ * ‍EXPECTS TOTAL OPERATING EXPENSES OF BETWEEN $29 MILLION AND $31 MILLION FOR YEAR ENDING DECEMBER 31, 2018​ * QTRLY NET LOSS PER COMMON SHARE $0.26 * ‍CURRENT CASH POSITION WILL BE SUFFICIENT TO FUND ITS OPERATIONS INTO Q4 OF 2018​ * Q4 EARNINGS PER SHARE VIEW $-0.27 — THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-03-15T12:33:00.000+02:00", "crawled": "2018-03-15T12:58:45.025+02:00", "highlightTitle": ""}